 |
Patients must live with uncertainty until concerns over key trial data are addressed Related items from OnMedica Extending anticoagulation duration cuts risk of VTE recurrence Metformin lowers cardiac deaths better than other drugs US doctor says FDA should have withdrawn rosuvastatin NICE calls for safer use of controlled drugs BMJ questions trial evidence for rivaroxaban |
Thursday, 29 September 2016
Pharma withheld faulty device info in rivaroxaban trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment